Perfusión aislada de extremidades. Experiencia inicial del Instituto Nacional de Cancerología, 2007-2008

AriyanCE, MS Brady. History of regional chemotherapy for cancer of the extremities. Int J Hyperthermia. 2008;24:185-92.

https://doi.org/10.1080/02656730701785102

Kettelhack Ch, Kraus T, Hupp T. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol. 1990;16:370-5.

Liénard D, Eggermont AM, Kroon BB, et al. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol. 1998;14:202-9.

https://doi.org/10.1002/(SICI)1098-2388(199804/05)14:3<202::AID-SSU3>3.0.CO;2-C

Instituto Nacional de Cancerología (INC)-Ministerio de la Protección Social(MPS) (Colombia). Anuario estadístico 2007. Bogotá: INC-MPS; 2008.

Creech O, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-32.

https://doi.org/10.1097/00000658-195810000-00009

Creech O, Krementz ET, Ryan RF, et al. Experiences with isolation-perfusion technics in the treatment of cancer. Ann Surg. 1959;149:627-39.

https://doi.org/10.1097/00000658-195905000-00003

Wieberdink J, Benkuizen C, Braat RP, et al. Dosimetry in isolated perfusion of the limbs assessment of perfused tissue volume and grading of toxic reactions. Eur J Cancer Clin Oncol. 1982;18:905-50.

https://doi.org/10.1016/0277-5379(82)90235-8

Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4:429-37.

https://doi.org/10.1016/S1470-2045(03)01141-0

Thompson JF, Good PD, Kam PCA. Hyperthermic isolated limb perfusion in the treatment of melanoma: technical aspects. Reg Cancer Treat. 1994;7:147-54.

Krementz ET, Sutherland CM, Muchmore JH. Isolated hyperthermia chemotherapy perfusion for limb melanoma. Surg Clin North Am. 1996;76:1313-30.

https://doi.org/10.1016/S0039-6109(05)70517-X

Therase P, Arbuck S, Eisenhauer E, et al. New guideline to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-16.

https://doi.org/10.1093/jnci/92.3.205

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.

https://doi.org/10.1016/j.ejca.2008.10.026

Klopp C, Alford TC, Bateman J, et al. Fractionated intra-arterial cancer chemotherapy with methyl bis-amine hydrochloride; a preliminary report. Ann Surg. 1950;132:811-32.

https://doi.org/10.1097/00000658-195010000-00018

Creech OJ, Ryan R, Krementz A. Treatment of malignant melanoma by isolated perfusion technique. JAMA 1959;169:339-43.

https://doi.org/10.1001/jama.1959.03000210033008

Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 1967;20:1351-81.

https://doi.org/10.1002/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO;2-#

Stehlin JS Jr, Giovanella BC, de Ipolyi PD, et al. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet. 1975;140:339-48.

Golomb FM, Postel AH, Hall AB, et al. Chemotherapy of human cancer by regional perfusion. Report of 52 perfusions. Cancer. 1962;15:828-45.

https://doi.org/10.1002/1097-0142(196207/08)15:4<828::AID-CNCR2820150420>3.0.CO;2-8

Austen WG, Monaco AP, Richardson GS, et al. Treatment of malignant pelvic tumors by extracorporeal perfusion with chemotherapeutic agents. N Engl J Med. 1959;261:1037-45.

https://doi.org/10.1056/NEJM195911192612101

Jesse RH. Technique of perfusion and infusion of head and neck. Cancer Chemother Rep. 1960;10:21-2.

Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.

https://doi.org/10.1200/JCO.1992.10.1.52

Eggermont AM, Schraffordt Koops H, Liénard D, et al. Isolated limb perfusion with highdose tumor necrosis factoralpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996;14: 2653-65.

https://doi.org/10.1200/JCO.1996.14.10.2653

Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224:756-64.

https://doi.org/10.1097/00000658-199612000-00011

Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Limb salvage by isolated perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: result of 270 perfusions in 247 patients. J Clin Oncol. 1999;11:497.

Lejeune FJ, Pujol N, Liénard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for nonresectable soft tissue sarcoma of the extremities. Eur J Surg Oncol. 2000;26:669-78.

https://doi.org/10.1053/ejso.2000.0979

Calvo Aller E, Arcas Meca R, Crespo de la Jara A, et al. Perfusión de extremidad aislada en Oncología. Rev Oncol. 2003;5:128-38.

Fraker DL. Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol. 2004;5:173-84.

https://doi.org/10.1007/s11864-004-0009-3

Duprat JP, Domingues AL, Coelho EG et al. Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma. Eur J Surg Oncol. 2009;35:568-72.

https://doi.org/10.1016/j.ejso.2008.10.002

Olieman AF, Liénard D, Eggermont AM, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg. 1999;134:303-7.

https://doi.org/10.1001/archsurg.134.3.303

Koops S, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol. 1998;16:2906-12.

https://doi.org/10.1200/JCO.1998.16.9.2906

Hafström L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol. 1991;9:2091-4.

https://doi.org/10.1200/JCO.1991.9.12.2091

Grünhagen DJ, Brunstein F, Graveland WJ, et al. Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol. 2005;12:473-9.

https://doi.org/10.1245/ASO.2005.03.059

Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24:4196-201.

https://doi.org/10.1200/JCO.2005.05.5152

Kroon BB, Noorda E, Vrouenraets BC, et al. Isolated limb perfusion for melanoma. Surg Oncol Clin N Am. 2008;17:785-94.

https://doi.org/10.1016/j.soc.2008.04.005

Moreno Ramirez D, de la Cruz Merino L, Ferrándiz Pulido L, et al. Perfusión de miembro aislado en el tratamiento del melanoma y del sarcoma de partes blandas. [Isolated limb perfusion for locally advanced melanoma and soft tissue sarcoma: executive summary]. Madrid: Ministerio de ciencia e Innovación. Instituto de salud Carlos III. Informe de Evaluación de Tecnologías Sanitarias (AETSA); 2007.

Blum RH, Edmonson J, Ryan L, et al. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 1993;31(Suppl 2):S238-40.

Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276-85.

https://doi.org/10.1200/JCO.1993.11.7.1276